Loading
AI
Arcellx, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 23 Jun 2022.
Arcellx, Inc.: what insiders have been doing
This page follows insider dealings at Arcellx, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. In the past year (18 October 2025 to 18 October 2026), 32 filings came from 7 insiders.
There is no open-market purchase to report; the filings show 3 sales worth €831k by 2 insiders. One trade stands out by size: a sale of €418k from Heery Christopher, disclosed on 13 January 2026.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
For context, the typical company on the same exchange (median of 5,808 companies) published 19 filings over the same period, against 32 filings here. Over the whole record (from 2022), the tally stands at 1 purchase and 67 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 22.3 m USD and net income at -228.9 m USD.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
191
Thresholds
n/a
Buy Volume
€5M
1 ops. · all time
Sell Volume
€122M
67 ops. · all time
Who traded when
BuySaleKavita Patel12 sales
Michelle Gilson11 sales
Christopher Heery8 sales
David Charles Lubner1 sale
Since the insiders bought
- +70.0%Entry US$18.60 · Close at T+365 US$31.62
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Arcellx, Inc. Hold (neutral), based on 10 analysts. Average price target: US$112.20.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$115.07
Analyst consensus
10 analystsHold
US$82.00Target US$112.20(-2%)US$120.00
Income statement
RevenueUS$22.3M
EBITDA-US$222.2M-997% margin
Net income-US$228.9M-1027.3% margin
Valuation
PER (forward)-77.7x
P/Book16.6x
Beta0.25
Balance sheet & cash
Market capUS$6.7B
Total debtUS$51.9M
Free Cash Flow-US$212.6M
Debt / Equity13%
Profitability & ownership
ROE-53.4%
ROA-24.1%
% insiders11.7%
% institutions90.3%
Last declaration on 28 April 2026
Declarations191 total
174,887 sharesCommon StockSEC:0001613689-26-000009:0
198,000 sharesCommon StockSEC:0001613689-26-000009:1
218,500 sharesCommon StockSEC:0001613689-26-000009:2
1,925 sharesCommon StockSEC:0001193125-26-187305:0
2,706 sharesCommon StockSEC:0001193125-26-187305:1
1,479,148 sharesCommon StockSEC:0001193125-26-188029:0
5,000 sharesCommon StockSEC:0001417976-26-000002:0
21,659 sharesCommon StockSEC:0001572000-26-000002:0
101,164 sharesCommon StockSEC:0001613689-26-000009:3
23,749 sharesCommon StockSEC:0001789632-26-000010:0
67,048 sharesCommon StockSEC:0001930862-26-000008:0
5,000 sharesCommon StockSEC:0001930862-26-000008:1
36,000 shares@ US$8.660.0045% mcap4.7% of flowCommon StockSEC:0001193125-26-161748:0
2,110 shares@ US$8.660.0003% mcap0.3% of flowCommon StockSEC:0001193125-26-161748:1
5,000 shares0Common StockSEC:0001193125-26-116340:0
101,164 shares0Common StockSEC:0001193125-26-092135:0
55,459 shares0Common StockSEC:0001193125-26-083657:0
20,530 shares0Common StockSEC:0001193125-26-072579:0
15,340 shares0Common StockSEC:0001193125-26-059840:0
20,496 shares0Common StockSEC:0001193125-26-057469:0
198,000 shares0Common StockSEC:0001613689-26-000005:0
218,500 shares0Common StockSEC:0001613689-26-000004:0
6,000 shares@ US$75.0092.3% of flowCommon StockSEC:0001193125-26-017002:1
6,000 shares@ US$6.287.7% of flowCommon StockSEC:0001193125-26-017002:0
13,064 shares0Common StockSEC:0001193125-26-013284:0
25 of 191 declarations
About Arcellx, Inc.
Arcellx, Inc. (NASDAQ: ACLX) is a U.S.-listed biotechnology company focused on cell therapy, primarily for oncology. Founded in December 2014, the company was established to bring more control and adaptability to the promise of cell therapy. Its corporate headquarters are in Redwood City, California, in the United States, and its business model is that of a clinical-stage biotech, meaning value creation is still heavily tied to clinical milestones, regulatory approvals, and strategic partnerships. ([arcellx.com](https://www.arcellx.com/company/?utm_source=openai))
Arcellx’s platform is built around its proprietary D-Domain technology, which underpins two main technology families: ddCAR and ARC-SparX. The company describes its mission as engineering cell therapies that are safer, more effective, and more broadly accessible. Its lead program is anitocabtagene autoleucel, or anito-cel, an autologous BCMA-targeted cell therapy candidate in relapsed/refractory multiple myeloma. Arcellx has also advanced earlier programs such as CART-ddBCMA and ACLX-001, the first ARC-SparX program to enter clinical development. ([arcellx.com](https://www.arcellx.com/company/?utm_source=openai))
Read moreShow less
From a competitive standpoint, Arcellx operates in a highly capital-intensive and crowded field, competing against established cell-therapy developers and large pharma companies with deeper manufacturing, regulatory, and commercial resources. Its differentiation lies in its proprietary binder and platform design, which the company believes can deliver better control and potentially improved safety and efficacy. That positioning matters in multiple myeloma, where patients often receive several prior lines of therapy and treatment options can remain limited. Arcellx’s global strategic collaboration with Kite, a Gilead company, is an important industrial endorsement and potentially expands the long-term commercial path for anito-cel. ([arcellx.com](https://www.arcellx.com/company/?utm_source=openai))
Recent developments have remained centered on anito-cel and the company’s myeloma franchise. In 2025, Arcellx reported new positive data from its pivotal Phase 2 iMMagine-1 study, presented at ASH, supporting the program’s clinical narrative. The company’s 2024 Form 10-K also notes that Kite initiated a global randomized Phase 3 study, iMMagine-3, in second- through fourth-line relapsed/refractory multiple myeloma. In early 2026, Arcellx’s website highlighted additional Tandem meeting presentations and messaging around early CAR T access. For investors, the key takeaway is that Arcellx remains a high-upside NASDAQ biotech in the United States, with a lead asset that has advanced meaningfully, but with the usual clinical, regulatory, and execution risks inherent to late-stage cell therapy development. ([arcellx.com](https://www.arcellx.com/wp-content/uploads/2025/12/12.6.25_Arcellx_iMMagine_1_ASH-Data.pdf?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
